BC Week In Review | Mar 29, 2019
Clinical News

Alkahest’s AKST4290 improves visual acuity in Phase IIa for AMD

Alkahest said AKST4290 led to a mean improvement of 7 letters in best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart from baseline to week six in...
Items per page:
1 - 1 of 1